# Nancy Stagliano

> Nancy E. Stagliano is a scientist, engineer, and biotechnology executive who co-founded CytomX Therapeutics and served as its early CEO. She later led iPierian and co-founded and led True North Therapeutics through their respective acquisitions. She is CEO and board chair of Neuron23 and executive chair of Sundance Biosciences, with additional board leadership roles at Star Therapeutics and Electra Therapeutics.

- **Role:** Chief Executive Officer and Board Chair at Neuron23; Executive Chair at Sundance Biosciences
- **Organizations:** CytomX Therapeutics, CytomX LLC, Cynvenio Biosystems, Millennium Pharmaceuticals, iPierian, True North Therapeutics, Neuron23, Sundance Biosciences, Star Therapeutics, Electra Therapeutics, Westlake Village BioPartners, New Leaf Venture Partners
- **Education:** B.S. in Electrical Engineering, Drexel University, M.S. in Biomedical Engineering, Drexel University, Ph.D. in Neuroscience, University of Miami, Postdoctoral research fellowship, Massachusetts General Hospital and Harvard Medical School
- **Known for:** Co-founded CytomX Therapeutics and co-invented its foundational platform., Led iPierian through its acquisition by Bristol-Myers Squibb in 2014., Co-founded and led True North Therapeutics through its acquisition by Bioverativ in 2017.

## Career timeline

- **1996** — Completed her Ph.D. in neuroscience at the University of Miami.
- **Late 1990s** — Entered the Cambridge biotechnology industry; spent approximately eight years at Millennium Pharmaceuticals.
- **2008** — Co-founded CytomX Therapeutics and served as its early chief executive.
- **2010** — CytomX raised a $30 million Series B led by Third Rock Ventures with Roche Venture Fund participation and announced plans to relocate to the Bay Area.
- **2011-08** — Sean McCarthy succeeded her as CytomX CEO; she was to join its scientific advisory board and consult.
- **2011-09** — Joined iPierian as CEO.
- **2013** — Co-founded True North Therapeutics, a spinout from iPierian; served as CEO of both companies.
- **2014-04** — Bristol-Myers Squibb acquired iPierian for $175 million upfront, with up to $550 million in milestones and future royalties.
- **2017-06** — Bioverativ completed the True North acquisition for $400 million upfront plus assumed cash, with up to $425 million in milestones.
- **2018-06** — Became chair of Star Therapeutics.
- **2018-10** — Became chair of Neuron23.
- **2019-03** — Became chair and a board member of Electra Therapeutics.
- **2020-10** — Became CEO of Neuron23, retaining the chair role.
- **2026-01** — Became executive chair of Sundance Biosciences.

## Achievements

- Co-founded CytomX Therapeutics and co-invented its foundational platform.
- Led iPierian through its acquisition by Bristol-Myers Squibb in 2014.
- Co-founded and led True North Therapeutics through its acquisition by Bioverativ in 2017.
- Holds patents and has published scientific research.
- Mentors first-time CEOs and emerging entrepreneurs.

## Latest updates

- **2026-01** — Became executive chair of Sundance Biosciences, as dated in her Electra leadership biography.
- **2026-04** — Featured in the Spring 2026 edition of University of Miami Medicine, discussing her career and mentoring.
- **2025-06** — Neuron23 announced a $96.5 million Series D financing while she served as CEO.

## Links

- LinkedIn: https://www.linkedin.com/in/nancy-stagliano-a40b893

---

Profile page: https://yespress.io/nancy-stagliano
Published by YesPress — https://yespress.io
Last updated: 2026-10-11